SEATTLE, May 13, 2011 /PRNewswire/ — Amnis Corporation, a
manufacturer of advanced cell imaging systems, today announced the
launch of the new FlowSight imaging flow cytometer.
The FlowSight is a compact and affordable 12-channel flow
cytometer with unrivalled fluorescence sensitivity and the
breakthrough ability to produce imagery of every cell. The modular
FlowSight can be upgraded in the factory or the field with up to
four lasers, a 96-well AutoSampler, and a Quantitative Imaging
package, thereby providing the capabilities and flexibility to meet
the needs of a broad range of users.
“With 12 detection channels, visual verification of every cell,
and affordable pricing, the FlowSight is designed to serve the
needs of beginners and expert flow cytometrists, alike,” said David
Basiji, Ph.D., Amnis’ Chief Executive Officer. Basiji added, “The
FlowSight complements Amnis’ flagship ImageStreamX imaging flow
cytometer, a high resolution microscope for cells in fluid
suspension that enables numerous image-based assays in rare
sub-populations.”
“The FlowSight is based on the proven ImageStreamX architecture
and shares its remarkable fluorescence sensitivity, exceeding that
of high-end conventional flow cytometers by five-fold or more,”
remarked William Ortyn, Amnis’ President and COO. “With the
FlowSight, Amnis is fulfilling its promise to bring cell imaging to
the larger flow cytometry market,” added Ortyn.
About Amnis: Amnis Corporation, headquartered in Seattle,
WA, develops, manufactures and markets instrumentation for high
speed cell imaging for research and diagnostic markets.
www.amnis.com
‘/>”/>
SOURCE
